scholarly journals Isolation and optimization of camelid single-domain antibodies: Dirk Saerens’ work on Nanobodies

2010 ◽  
Vol 1 (7) ◽  
pp. 235 ◽  
Author(s):  
Dirk Saerens
Keyword(s):  
Single Domain ◽  
Single Domain Antibodies

Development and Testing of Recombinant Single Domain Antibodies

2010 ◽  
Author(s):  
Ellen Goldman ◽  
Andrew Hayhurst
Keyword(s):  
Single Domain ◽  
Single Domain Antibodies

Engineering of single-domain antibodies for next generation snakebite antivenoms

2021 ◽  
Author(s):  
Carla F.C. Fernandes ◽  
Soraya S. Pereira ◽  
Marcos B. Luiz ◽  
Nauanny K.R.L. Silva ◽  
Marcela Cristina da Silva ◽  
...  
Keyword(s):  
Single Domain ◽  
Next Generation ◽  
Single Domain Antibodies

scholarly journals Single-domain antibodies make a difference

Science ◽  
2021 ◽  
Vol 371 (6530) ◽  
pp. 681-682 ◽  
Author(s):  
Xavier Saelens ◽  
Bert Schepens
Keyword(s):  
Single Domain ◽  
Single Domain Antibodies

scholarly journals Nanobodies: new avenue to treat kidney disease

2021 ◽  
Author(s):  
Nicola Wanner ◽  
Thomas Eden ◽  
Nastassia Liaukouskaya ◽  
Friedrich Koch-Nolte
Keyword(s):  
Kidney Disease ◽  
Single Domain ◽  
Therapeutic Options ◽  
Renal Diseases ◽  
Single Domain Antibodies ◽  
Potential Use ◽  
Disease Specific

AbstractCurrent therapeutic options for renal diseases are limited, and the search for disease-specific treatments is ongoing. Nanobodies, single-domain antibodies with many advantages over conventional antibodies, provide flexible, easy-to-format biologicals with many possible applications. Here, we discuss the potential use of nanobodies for renal diseases.

scholarly journals Single Domain Antibodies as Carriers for Intracellular Drug Delivery: A Proof of Principle Study

Biomolecules ◽  
2021 ◽  
Vol 11 (7) ◽  
pp. 927
Author(s):  
Sebas D. Pronk ◽  
Erik Schooten ◽  
Jurgen Heinen ◽  
Esra Helfrich ◽  
Sabrina Oliveira ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Targeted Delivery ◽  
Single Domain ◽  
Drug Conjugates ◽  
Intracellular Drug Delivery ◽  
Internalization Rate ◽  
Single Domain Antibodies ◽  
Different Characteristics

Antibody-drug conjugates (ADCs) are currently used for the targeted delivery of drugs to diseased cells, but intracellular drug delivery and therefore efficacy may be suboptimal because of the large size, slow internalization and ineffective intracellular trafficking of the antibody. Using a phage display method selecting internalizing phages only, we developed internalizing single domain antibodies (sdAbs) with high binding affinity to rat PDGFRβ, a receptor involved in different types of diseases. We demonstrate that these constructs have different characteristics with respect to internalization rates but all traffic to lysosomes. To compare their efficacy in targeted drug delivery, we conjugated the sdAbs to a cytotoxic drug. The conjugates showed improved cytotoxicity correlating to their internalization speed. The efficacy of the conjugates was inhibited in the presence of vacuolin-1, an inhibitor of lysosomal maturation, suggesting lysosomal trafficking is needed for efficient drug release. In conclusion, sdAb constructs with different internalization rates can be designed against the same target, and sdAbs with a high internalization rate induce more cell killing than sdAbs with a lower internalization rate in vitro. Even though the overall efficacy should also be tested in vivo, sdAbs are particularly interesting formats to be explored to obtain different internalization rates.

A simple quantitative affinity capturing assay of poliovirus antigens and subviral particles by single-domain antibodies using magnetic beads

2011 ◽  
Vol 173 (2) ◽  
pp. 300-305 ◽  
Author(s):  
Bert Thys ◽  
Dirk Saerens ◽  
Lise Schotte ◽  
Gerrit De Bleeser ◽  
Serge Muyldermans ◽  
...  
Keyword(s):  
Magnetic Beads ◽  
Single Domain ◽  
Single Domain Antibodies ◽  
Subviral Particles
Sign in / Sign up

Export Citation Format

Share Document